The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia

Aberrantly expressed tyrosine kinases have emerged as promising targets for drug development in acute myeloid leukemia (AML). We report that AKN-028, a novel tyrosine kinase inhibitor (TKI), is a potent FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor (IC(50)=6 nℳ), causing dose-dependent inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Eriksson, A, Hermanson, M, Wickström, M, Lindhagen, E, Ekholm, C, Jenmalm Jensen, A, Löthgren, A, Lehmann, F, Larsson, R, Parrow, V, Höglund, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432483/
https://www.ncbi.nlm.nih.gov/pubmed/22864397
http://dx.doi.org/10.1038/bcj.2012.28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432483/
https://www.ncbi.nlm.nih.gov/pubmed/22864397
http://dx.doi.org/10.1038/bcj.2012.28

Ejemplares similares